Clinical studies
AROS has built an expertise and infrastructure that supports clinical
studies. AROS is able to receive the blood samples, isolate DNA/RNA,
bank the samples for extended periods, analyze haplotypes/genotypes,
identify gene signatures/pathways, and report this in a GLP compliant
fashion usable for regulatory submissions.
AROS can perform this in a low cost high throughput fashion.
Clinical Trials
AROS has expertise in genotyping responders/ non-responders
or slow/ fast metabolizers based on SNP arrays; as well as identifying
gene expression signatures that will identify responders/ non-responders
or track patients with a high likelihood of side-effects. AROS offers
identification of key pathways using bioinformatic tools, that reflect
drug action and side-effects on an individual patient basis.
AROS supports the customer from blood has been drawn to data are reported in a regulatory submission compliant format.
Thanks to high throughput robotics, AROS is able to handle thousands of samples in a short time frame.
Cancer
AROS scientists have many years of experience in cancer research,
and a long and prestigious publication record in that area (see publications). AROS
has performed multiple studies that include aspects as
• Laser microdissection of samples before isolation of DNA/RNA/miRNA
• PCR – based testing of microsatellite imbalance
• Identification of predictive signatures
• Identification of new drug targets
AROS has been able to supply large cohorts of patients based on its close relation to the University Hospital of Aarhus, that owns part of the company, as well as other collaborators. This activity needs an ethical approval by local authorities.
Association studies using SNP arrays
In populations where properties
are shared between groups of individuals it is now possible to associate
these properties to specific genotypes. AROS scientists have used this
for construction of haplotypes associated with diseases like mental disorders,
and for identification of genotypes related to reduced drug response.
Drug rescue
Some new drug candidates may unfortunately show a low response
rate or unwanted side effects. AROS provides technologies like massive
global SNP genotyping and global expression monitoring that on blood
samples may identify genotypes or signatures that identify the good responders
and reveal the nature of side effects. AROS has experience in these
studies and has participated in rescue of several drug candidates, where
mechanisms of action among similar compounds were identified, and also
the triggering events leading to side effects.